網膜障害治療市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、剤形別、流通チャネル別、地域別、競合市場別、2020年～2030年

網膜障害治療の世界市場規模は2024年に150億2,000万米ドル、2030年には256億米ドルに達すると予測、CAGRは9.25%。

世界の網膜障害治療市場は、人口動態の変化、世界の疾患罹患率の上昇、精密・再生治療薬における技術革新の波に後押しされ、変革の極めて重要な局面を迎えています。加齢黄斑変性症（AMD）、糖尿病性網膜症（DR）、網膜静脈閉塞症（RVO）、網膜色素変性症などの疾患は、高負担で視力を脅かす疾患であり、アンメット・クリニカル・ニーズが高いです。この持続的な市場拡大の原動力となっているのは、患者基盤の拡大と、臨床治療プロトコルを再構築しつつある先進生物製剤、遺伝子標的治療薬、長時間作用型ドラッグデリバリーシステムの採用拡大です。疾病の安定化に主眼が置かれた以前の時代とは異なり、現在の市場は、神経再生、視覚機能の回復、治療効果の持続性に重点が置かれるようになるなど、回復的転帰への移行を反映しています。

主な市場促進要因

網膜疾患の有病率の上昇

主な市場課題

高い治療費と限られた手頃な価格

主要市場動向

長時間作用型および徐放性治療薬へのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 網膜障害治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（黄斑変性、糖尿病網膜症、その他）
  • 剤形別（ゲル、点眼液、カプセル・錠剤、点眼薬、軟膏）
  • 流通チャネル別（病院薬局、オンライン薬局、小売薬局）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の網膜障害治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の網膜障害治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の網膜障害治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の網膜障害治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの網膜障害治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の網膜障害治療市場：SWOT分析

第14章 競合情勢

• Santen Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals Inc.
• Graybug Vision, Inc.
• Shire plc（Takeda Pharmaceutical Company Limited）
• Bayer AG
• AbbVie Inc.
• Genentech（F. Hoffmann-La Roche Ltd）
• Kubota Vision Inc.
• Pfizer, Inc.
• Bausch+Lomb

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Retinal Disorder Treatment market was valued at USD 15.02 Billion in 2024 and is expected to reach USD 25.60 Billion by 2030 with a CAGR of 9.25%.

The Global Retinal Disorder Treatment Market is entering a pivotal phase of transformation, propelled by demographic shifts, rising global disease incidence, and a wave of innovation in precision and regenerative therapeutics. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion (RVO), and retinitis pigmentosa continue to represent high-burden, sight-threatening disorders with considerable unmet clinical need. This sustained market expansion is being fueled by a growing patient base and increased adoption of advanced biologics, gene-targeted therapies, and long-acting drug delivery systems that are reshaping clinical treatment protocols. Unlike previous eras focused primarily on disease stabilization, the current market trajectory reflects a transition toward restorative outcomes, with a growing emphasis on neural regeneration, visual function recovery, and durability of therapeutic response.

Key Market Drivers

Rising Prevalence of Retinal Disorders

The increasing prevalence of retinal disorders is a fundamental factor fueling the expansion of the Global Retinal Disorder Treatment Market. Globally, over 2.2 billion people are affected by near or distance vision impairment. Notably, in at least 1 billion of these cases, the impairment was either preventable or remains untreated highlighting a significant unmet need and an addressable market opportunity for eye care solutions. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and retinitis pigmentosa are becoming increasingly common across global populations. The global burden of age-related macular degeneration (AMD) is on a sharp upward trajectory, driven by demographic aging. Prevalence reached approximately 196 million cases in 2020 and is forecasted to rise to 288 million by 2040 representing a 47% increase over two decades and signaling a growing demand for targeted retinal therapies and long-term disease management solutions.

Diabetic retinopathy remains one of the most common complications of diabetes. According to the International Diabetes Federation, over 530 million people are living with diabetes worldwide, a number projected to rise sharply in the coming decades. Between 1990 and 2022, the global diabetic population grew more than fourfold from 200 million to 830 million underscoring a dramatic escalation in metabolic health challenges. In 2021 alone, diabetes and diabetes-related kidney disease accounted for over 2 million deaths. Additionally, elevated blood glucose levels were responsible for approximately 11% of all cardiovascular-related fatalities, reinforcing the urgent need for integrated diagnostic, therapeutic, and monitoring solutions across the healthcare value chain. Poor dietary habits, lack of physical activity, and high rates of smoking and obesity are increasing the risk factors for retinal disorders in both developed and developing countries. This expanding patient population directly translates into higher demand for ongoing treatment and management solutions, thereby driving market growth.

Many retinal disorders are chronic and progressive, requiring long-term or lifelong treatment. For instance, patients diagnosed with wet AMD typically undergo regular intravitreal injections of anti-VEGF agents. This recurrent treatment model generates sustained revenue streams for pharmaceutical companies and significantly contributes to market scalability. Additionally, the long-term nature of retinal diseases encourages investment in patient monitoring, follow-up diagnostics, and personalized therapies, creating commercial opportunities across various segments of the treatment ecosystem. Untreated or poorly managed retinal disorders can lead to severe vision impairment or blindness, resulting in reduced quality of life, productivity losses, and increased caregiver burden.

This economic and social impact has prompted governments and healthcare providers to allocate more resources to preventive care, early detection, and timely treatment. As a result, there is increased public and private investment in eye health infrastructure, awareness campaigns, and affordable access to retinal care further accelerating market expansion. The rising prevalence of retinal disorders incentivizes pharmaceutical, biotech, and medical device companies to expand their treatment portfolios. This includes developing novel therapeutics such as: Long-acting anti-VEGF agents, Gene therapies and cell-based interventions, Sustained-release drug delivery systems. This diversification meets the varied needs of a growing and heterogeneous patient population, supporting deeper market penetration and broader product adoption.

Key Market Challenges

High Cost of Treatment and Limited Affordability

Retinal disorder treatments particularly anti-VEGF therapies, advanced diagnostics (like Optical Coherence Tomography), and retinal surgeries are often prohibitively expensive, especially in low- and middle-income markets. The recurring nature of treatment (e.g., monthly injections for wet AMD) further compounds financial burden on patients.

This cost barrier significantly limits market penetration in price-sensitive regions. Even in developed economies, budget constraints in public health systems and restricted reimbursement policies pose challenges for long-term patient adherence. For industry stakeholders, Reduced patient retention and compliance, Pricing pressure from governments and insurance providers, Limited scalability of premium therapies in emerging markets. To achieve sustained growth, companies need to invest in cost-effective delivery models, biosimilars, and pricing strategies tailored to diverse economic segments.

Key Market Trends

Shift Toward Long-Acting and Sustained-Release Therapies

One of the most transformative developments in retinal care is the industry-wide move toward long-acting formulations and sustained-release drug delivery systems. Traditional treatments such as monthly intravitreal injections for wet AMD have been effective but come with challenges related to patient compliance, clinical burden, and healthcare costs. Port delivery systems (e.g., Genentech's Susvimo), Extended-duration anti-VEGF agents (e.g., Vabysmo, Eylea HD), Biodegradable implants and micro-pumps under clinical development.

This trend enhances patient adherence, reduces the frequency of clinic visits, and improves overall treatment outcomes critical factors for long-term market growth. For pharmaceutical and biotech companies, it opens opportunities to: Differentiate their offerings with more convenient and premium solutions, Command pricing premiums for innovation. Capture broader patient segments, especially those currently under-treated due to procedural fatigue or logistical barrier. As the market continues to shift toward durability and patient-centric delivery, players that invest in sustained-release platforms are expected to gain a competitive edge.

Key Market Players

• Santen Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals Inc.
• Graybug Vision, Inc.
• Shire plc (Takeda Pharmaceutical Company Limited)
• Bayer AG
• AbbVie Inc.
• Genentech (F. Hoffmann-La Roche Ltd)
• Kubota Vision Inc.
• Pfizer, Inc.
• Bausch + Lomb

Report Scope:

In this report, the Global Retinal Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Retinal Disorder Treatment Market, By Product:

• Macular Degeneration
• Diabetic Retinopathy
• Others

Retinal Disorder Treatment Market, By Dosage Form:

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Retinal Disorder Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Retinal Disorder Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Retinal Disorder Treatment Market.

Available Customizations:

Global Retinal Disorder Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Retinal Disorder Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Macular Degeneration, Diabetic Retinopathy, Others)
  • 5.2.2. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Retinal Disorder Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Dosage Form
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Retinal Disorder Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Dosage Form
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Retinal Disorder Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Dosage Form
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Retinal Disorder Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Dosage Form
      • 6.3.3.2.3. By Distribution Channel

7. Europe Retinal Disorder Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Dosage Form
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Retinal Disorder Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Dosage Form
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Retinal Disorder Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Dosage Form
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Retinal Disorder Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Dosage Form
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Retinal Disorder Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Dosage Form
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Retinal Disorder Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Dosage Form
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Retinal Disorder Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Dosage Form
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Retinal Disorder Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Dosage Form
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Retinal Disorder Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Dosage Form
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Retinal Disorder Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Dosage Form
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Retinal Disorder Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Dosage Form
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Retinal Disorder Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Dosage Form
      • 8.3.5.2.3. By Distribution Channel

9. South America Retinal Disorder Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Dosage Form
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Retinal Disorder Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Dosage Form
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Retinal Disorder Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Dosage Form
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Retinal Disorder Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Dosage Form
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Retinal Disorder Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Dosage Form
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Retinal Disorder Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Dosage Form
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Retinal Disorder Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Dosage Form
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Retinal Disorder Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Dosage Form
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Retinal Disorder Treatment Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Santen Pharmaceutical Co., Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Regeneron Pharmaceuticals Inc.
• 14.3. Graybug Vision, Inc.
• 14.4. Shire plc (Takeda Pharmaceutical Company Limited)
• 14.5. Bayer AG
• 14.6. AbbVie Inc.
• 14.7. Genentech (F. Hoffmann-La Roche Ltd)
• 14.8. Kubota Vision Inc.
• 14.9. Pfizer, Inc.
• 14.10.Bausch + Lomb

15. Strategic Recommendations

16. About Us & Disclaimer